Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 8/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29660566 | 1.00 | LMNA (0.67) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL985189 | 0.95 | LMNA (0.73) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL30208112 | 0.95 | LMNA (0.73) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL3203878 | 0.86 | MAPT (0.90) | LMNAALDH1A1MAPTGPR119SMN1; SMN2 | |
| SCHEMBL25317704 | 0.86 | GPR119 (0.59) | LMNAALDH1A1MAPTGPR119 | |
| SCHEMBL29475535 | 0.86 | GPR119 (0.59) | LMNAALDH1A1MAPTGPR119 | |
| SCHEMBL6352848 | 0.84 | ALDH1A1 (0.56) | LMNAALDH1A1MAPTGPR119MET | |
| SCHEMBL30981331 | 0.83 | ALDH1A1 (0.57) | LMNAALDH1A1MAPTGPR119ENPP2 | |
| SCHEMBL13926625 | 0.83 | ALDH1A1 (0.57) | LMNAALDH1A1MAPTGPR119ENPP2 | |
| SCHEMBL29475574 | 0.83 | GPR119 (0.62) | LMNAALDH1A1MAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220347187-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO OPERATING COMPANY LLC | 2022-11-03 | — | — | US | disclosed |
| EP-4013743-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| CN-114502536-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021030623-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-2840080-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2840080-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-9145415-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9145415-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9145415-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2015-09-29 | — | — | US | disclosed |
| EP-2840080-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | Fujifilm Corporation (JP) | 2015-02-25 | — | — | EP | disclosed |
| EP-2840080-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | Fujifilm Corporation (JP) | 2015-02-25 | — | — | EP | disclosed |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-02-12 | — | — | US | disclosed |
| WO-2013157540-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | 富士フイルム株式会社 (JP) | 2013-10-24 | — | — | WO | disclosed |
| US-20070219234-A1 | Thienopyridine Derivatives | SANKYO COMPANY, LIMITED (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1764367-A1 | THIENOPYRIDINE DERIVATIVES | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045339-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FLT3, NPM1, ABL1 | LMNA 2941/4885ALDH1A1 2553/4885MAPT 3892/4885 |
| US-20220347187-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | LMNA 3004/4885ALDH1A1 2992/4885MAPT 3156/4885 |
| US-20070219234-A1 | Thienopyridine Derivatives | RASGRP1, NRAS, HRH3 | LMNA 4549/4885ALDH1A1 1073/4885MAPT 4452/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.